instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cerebellar atrophy'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | ACETAMINOPHEN, CERLIPONASE ALFA, DEXAMETHASONE | DrugsGivenReaction | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cerebral atrophy'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | ACETAMINOPHEN, CERLIPONASE ALFA, DEXAMETHASONE | DrugsGivenReaction | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cerebral disorder'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | ACETAMINOPHEN, CERLIPONASE ALFA, DEXAMETHASONE | DrugsGivenReaction | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cognitive disorder'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | ACETAMINOPHEN, CERLIPONASE ALFA, DEXAMETHASONE | DrugsGivenReaction | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fine motor skill dysfunction'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | ACETAMINOPHEN, CERLIPONASE ALFA, DEXAMETHASONE | DrugsGivenReaction | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Generalised tonic-clonic seizure'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | BACLOFEN, CERLIPONASE ALFA, CLOBAZAM, LAMOTRIGINE, LEVETIRACETAM, TRIHEXYPHENIDYL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33990214 | 19,443,443 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infusion related reaction'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | ACETAMINOPHEN, CERLIPONASE ALFA, DEXAMETHASONE | DrugsGivenReaction | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | ACETAMINOPHEN, CERLIPONASE ALFA, DEXAMETHASONE | DrugsGivenReaction | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | ACETAMINOPHEN, CERLIPONASE ALFA, DEXAMETHASONE | DrugsGivenReaction | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash maculo-papular'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | ACETAMINOPHEN, CERLIPONASE ALFA, DEXAMETHASONE | DrugsGivenReaction | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Seizure'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | BACLOFEN, CERLIPONASE ALFA, CLOBAZAM, LAMOTRIGINE, LEVETIRACETAM, TRIHEXYPHENIDYL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33990214 | 19,443,443 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sinus tachycardia'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | ACETAMINOPHEN, CERLIPONASE ALFA, DEXAMETHASONE | DrugsGivenReaction | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sleep disorder'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | BACLOFEN, CERLIPONASE ALFA, CLOBAZAM, LAMOTRIGINE, LEVETIRACETAM, TRIHEXYPHENIDYL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33990214 | 19,443,443 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Speech disorder developmental'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | ACETAMINOPHEN, CERLIPONASE ALFA, DEXAMETHASONE | DrugsGivenReaction | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'White matter lesion'. | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | ACETAMINOPHEN, CERLIPONASE ALFA, DEXAMETHASONE | DrugsGivenReaction | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
What was the administration route of drug 'CERLIPONASE ALFA'? | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | Intracisternal | DrugAdministrationRoute | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
What was the administration route of drug 'DEXAMETHASONE'? | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | Oral | DrugAdministrationRoute | CC BY | 33990214 | 19,317,998 | 2021-05-14 |
What was the dosage of drug 'BACLOFEN'? | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | UNKNOWN DOSE | DrugDosageText | CC BY | 33990214 | 19,443,443 | 2021-05-14 |
What was the dosage of drug 'CLOBAZAM'? | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | UNKNOWN DOSE | DrugDosageText | CC BY | 33990214 | 19,443,443 | 2021-05-14 |
What was the dosage of drug 'LAMOTRIGINE'? | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | UNKNOWN DOSE | DrugDosageText | CC BY | 33990214 | 19,443,443 | 2021-05-14 |
What was the dosage of drug 'LEVETIRACETAM'? | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | UNKNOWN DOSE | DrugDosageText | CC BY | 33990214 | 19,443,443 | 2021-05-14 |
What was the dosage of drug 'TRIHEXYPHENIDYL HYDROCHLORIDE'? | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | UNKNOWN DOSE | DrugDosageText | CC BY | 33990214 | 19,443,443 | 2021-05-14 |
What was the outcome of reaction 'Sleep disorder'? | Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa... | Not recovered | ReactionOutcome | CC BY | 33990214 | 19,443,443 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myocarditis'. | A 25-Year-Old Man with Refractory Schizophrenia and Clozapine-Induced Myocarditis Diagnosed by Non-Invasive Cardiovascular Magnetic Resonance.
BACKGROUND Clozapine, a second-generation antipsychotic, is often prescribed for refractory schizophrenia; however, it can cause life-threatening adverse events including agranu... | CLOZAPINE, HALOPERIDOL, OLANZAPINE, RISPERIDONE | DrugsGivenReaction | CC BY-NC-ND | 33990535 | 19,383,049 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pericardial effusion'. | A 25-Year-Old Man with Refractory Schizophrenia and Clozapine-Induced Myocarditis Diagnosed by Non-Invasive Cardiovascular Magnetic Resonance.
BACKGROUND Clozapine, a second-generation antipsychotic, is often prescribed for refractory schizophrenia; however, it can cause life-threatening adverse events including agranu... | CLOZAPINE, HALOPERIDOL, OLANZAPINE, RISPERIDONE | DrugsGivenReaction | CC BY-NC-ND | 33990535 | 19,383,049 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | A 25-Year-Old Man with Refractory Schizophrenia and Clozapine-Induced Myocarditis Diagnosed by Non-Invasive Cardiovascular Magnetic Resonance.
BACKGROUND Clozapine, a second-generation antipsychotic, is often prescribed for refractory schizophrenia; however, it can cause life-threatening adverse events including agranu... | CLOZAPINE, COLCHICINE, LISINOPRIL, METOPROLOL | DrugsGivenReaction | CC BY-NC-ND | 33990535 | 19,542,545 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | A 25-Year-Old Man with Refractory Schizophrenia and Clozapine-Induced Myocarditis Diagnosed by Non-Invasive Cardiovascular Magnetic Resonance.
BACKGROUND Clozapine, a second-generation antipsychotic, is often prescribed for refractory schizophrenia; however, it can cause life-threatening adverse events including agranu... | CLOZAPINE, HALOPERIDOL, OLANZAPINE, RISPERIDONE | DrugsGivenReaction | CC BY-NC-ND | 33990535 | 19,383,049 | 2021-05-15 |
What was the administration route of drug 'LISINOPRIL'? | A 25-Year-Old Man with Refractory Schizophrenia and Clozapine-Induced Myocarditis Diagnosed by Non-Invasive Cardiovascular Magnetic Resonance.
BACKGROUND Clozapine, a second-generation antipsychotic, is often prescribed for refractory schizophrenia; however, it can cause life-threatening adverse events including agranu... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33990535 | 19,542,545 | 2021-05-15 |
What was the outcome of reaction 'Myocarditis'? | A 25-Year-Old Man with Refractory Schizophrenia and Clozapine-Induced Myocarditis Diagnosed by Non-Invasive Cardiovascular Magnetic Resonance.
BACKGROUND Clozapine, a second-generation antipsychotic, is often prescribed for refractory schizophrenia; however, it can cause life-threatening adverse events including agranu... | Recovered | ReactionOutcome | CC BY-NC-ND | 33990535 | 19,383,049 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Adverse event'. | Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.
To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemic... | ADALIMUMAB, AZATHIOPRINE | DrugsGivenReaction | CC BY | 33990652 | 17,921,010 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.
To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemic... | ADALIMUMAB, AZATHIOPRINE | DrugsGivenReaction | CC BY | 33990652 | 17,921,010 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Inflammatory bowel disease'. | Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.
To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemic... | ADALIMUMAB, AZATHIOPRINE | DrugsGivenReaction | CC BY | 33990652 | 17,921,010 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Surgery'. | Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.
To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemic... | ADALIMUMAB, AZATHIOPRINE | DrugsGivenReaction | CC BY | 33990652 | 17,921,010 | 2021-05-14 |
What was the dosage of drug 'ADALIMUMAB'? | Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.
To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemic... | UNK UNK, Q2WK | DrugDosageText | CC BY | 33990652 | 17,921,010 | 2021-05-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac failure'. | Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension.
METHODS
In this retrospective observational study, we analyzed all patients with pulmonary arterial hypertension undergoing LenusPro® pump implantation between November... | CEFUROXIME, GENTAMICIN, REMIFENTANIL, SODIUM CHLORIDE, TREPROSTINIL, VANCOMYCIN | DrugsGivenReaction | CC BY | 33992098 | 19,458,523 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemodynamic instability'. | Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension.
METHODS
In this retrospective observational study, we analyzed all patients with pulmonary arterial hypertension undergoing LenusPro® pump implantation between November... | CEFUROXIME, GENTAMICIN, REMIFENTANIL, SODIUM CHLORIDE, TREPROSTINIL, VANCOMYCIN | DrugsGivenReaction | CC BY | 33992098 | 19,458,523 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy non-responder'. | Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension.
METHODS
In this retrospective observational study, we analyzed all patients with pulmonary arterial hypertension undergoing LenusPro® pump implantation between November... | TREPROSTINIL | DrugsGivenReaction | CC BY | 33992098 | 19,468,090 | 2021-05-15 |
What was the administration route of drug 'CEFUROXIME'? | Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension.
METHODS
In this retrospective observational study, we analyzed all patients with pulmonary arterial hypertension undergoing LenusPro® pump implantation between November... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33992098 | 19,458,523 | 2021-05-15 |
What was the administration route of drug 'TREPROSTINIL'? | Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension.
METHODS
In this retrospective observational study, we analyzed all patients with pulmonary arterial hypertension undergoing LenusPro® pump implantation between November... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33992098 | 19,468,090 | 2021-05-15 |
What was the dosage of drug 'REMIFENTANIL'? | Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension.
METHODS
In this retrospective observational study, we analyzed all patients with pulmonary arterial hypertension undergoing LenusPro® pump implantation between November... | CONTINUOUS INFUSION | DrugDosageText | CC BY | 33992098 | 19,458,523 | 2021-05-15 |
What was the outcome of reaction 'Cardiac failure'? | Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension.
METHODS
In this retrospective observational study, we analyzed all patients with pulmonary arterial hypertension undergoing LenusPro® pump implantation between November... | Recovered | ReactionOutcome | CC BY | 33992098 | 19,458,523 | 2021-05-15 |
What was the outcome of reaction 'Haemodynamic instability'? | Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension.
METHODS
In this retrospective observational study, we analyzed all patients with pulmonary arterial hypertension undergoing LenusPro® pump implantation between November... | Recovered | ReactionOutcome | CC BY | 33992098 | 19,458,523 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Concomitant disease aggravated'. | Severe hyperglycemia and insulin resistance in patients with SARS-CoV-2 infection: a report of two cases.
BACKGROUND
Severe insulin resistance is an uncommon finding in patients with type 2 diabetes but is often associated with difficult to managing blood glucose. While severe insulin resistance is most frequently seen... | ASCORBIC ACID, AZITHROMYCIN, HYDROXYCHLOROQUINE, METFORMIN HYDROCHLORIDE, METHYLPREDNISOLONE, SARILUMAB | DrugsGivenReaction | CC BY | 33992101 | 20,119,745 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Severe hyperglycemia and insulin resistance in patients with SARS-CoV-2 infection: a report of two cases.
BACKGROUND
Severe insulin resistance is an uncommon finding in patients with type 2 diabetes but is often associated with difficult to managing blood glucose. While severe insulin resistance is most frequently seen... | AZITHROMYCIN, HYDROXYCHLOROQUINE, METFORMIN HYDROCHLORIDE, METHYLPREDNISOLONE, SARILUMAB | DrugsGivenReaction | CC BY | 33992101 | 20,138,427 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Severe hyperglycemia and insulin resistance in patients with SARS-CoV-2 infection: a report of two cases.
BACKGROUND
Severe insulin resistance is an uncommon finding in patients with type 2 diabetes but is often associated with difficult to managing blood glucose. While severe insulin resistance is most frequently seen... | ASCORBIC ACID, AZITHROMYCIN, HYDROXYCHLOROQUINE, METFORMIN HYDROCHLORIDE, METHYLPREDNISOLONE, SARILUMAB | DrugsGivenReaction | CC BY | 33992101 | 20,119,745 | 2021-05-15 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | Severe hyperglycemia and insulin resistance in patients with SARS-CoV-2 infection: a report of two cases.
BACKGROUND
Severe insulin resistance is an uncommon finding in patients with type 2 diabetes but is often associated with difficult to managing blood glucose. While severe insulin resistance is most frequently seen... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33992101 | 20,168,407 | 2021-05-15 |
What was the dosage of drug 'ASCORBIC ACID'? | Severe hyperglycemia and insulin resistance in patients with SARS-CoV-2 infection: a report of two cases.
BACKGROUND
Severe insulin resistance is an uncommon finding in patients with type 2 diabetes but is often associated with difficult to managing blood glucose. While severe insulin resistance is most frequently seen... | UNK, HIGH DOSE | DrugDosageText | CC BY | 33992101 | 20,119,745 | 2021-05-15 |
What was the dosage of drug 'SARILUMAB'? | Severe hyperglycemia and insulin resistance in patients with SARS-CoV-2 infection: a report of two cases.
BACKGROUND
Severe insulin resistance is an uncommon finding in patients with type 2 diabetes but is often associated with difficult to managing blood glucose. While severe insulin resistance is most frequently seen... | UNK, ONCE/SINGLE | DrugDosageText | CC BY | 33992101 | 20,119,745 | 2021-05-15 |
What was the outcome of reaction 'Concomitant disease aggravated'? | Severe hyperglycemia and insulin resistance in patients with SARS-CoV-2 infection: a report of two cases.
BACKGROUND
Severe insulin resistance is an uncommon finding in patients with type 2 diabetes but is often associated with difficult to managing blood glucose. While severe insulin resistance is most frequently seen... | Recovering | ReactionOutcome | CC BY | 33992101 | 20,119,745 | 2021-05-15 |
What was the outcome of reaction 'Condition aggravated'? | Severe hyperglycemia and insulin resistance in patients with SARS-CoV-2 infection: a report of two cases.
BACKGROUND
Severe insulin resistance is an uncommon finding in patients with type 2 diabetes but is often associated with difficult to managing blood glucose. While severe insulin resistance is most frequently seen... | Recovering | ReactionOutcome | CC BY | 33992101 | 20,138,427 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Fatal Streptococcus pseudoporcinus disseminated infection in decompensated liver cirrhosis: a case report.
BACKGROUND
Streptococcus pseudoporcinus (S. pseudoporcinus) was first identified in 2006. It cross-reacts with Lancefield group B antigen agglutination reagents and has been misidentified as S. agalactiae. Sites o... | ALBUMIN HUMAN, DAPTOMYCIN, FUROSEMIDE, HYDROCORTISONE, INSULIN GLARGINE, MEROPENEM, SPIRONOLACTONE, TERLIPRESSIN | DrugsGivenReaction | CC BY | 33992114 | 19,537,572 | 2021-05-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug resistance'. | Fatal Streptococcus pseudoporcinus disseminated infection in decompensated liver cirrhosis: a case report.
BACKGROUND
Streptococcus pseudoporcinus (S. pseudoporcinus) was first identified in 2006. It cross-reacts with Lancefield group B antigen agglutination reagents and has been misidentified as S. agalactiae. Sites o... | ALBUMIN HUMAN, DAPTOMYCIN, FUROSEMIDE, HYDROCORTISONE, INSULIN GLARGINE, MEROPENEM, SPIRONOLACTONE, TERLIPRESSIN, VANCOMYCIN | DrugsGivenReaction | CC BY | 33992114 | 20,058,440 | 2021-05-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Multiple organ dysfunction syndrome'. | Fatal Streptococcus pseudoporcinus disseminated infection in decompensated liver cirrhosis: a case report.
BACKGROUND
Streptococcus pseudoporcinus (S. pseudoporcinus) was first identified in 2006. It cross-reacts with Lancefield group B antigen agglutination reagents and has been misidentified as S. agalactiae. Sites o... | ALBUMIN HUMAN, DAPTOMYCIN, FUROSEMIDE, HYDROCORTISONE, INSULIN GLARGINE, MEROPENEM, SPIRONOLACTONE, TERLIPRESSIN, VANCOMYCIN | DrugsGivenReaction | CC BY | 33992114 | 20,058,440 | 2021-05-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Fatal Streptococcus pseudoporcinus disseminated infection in decompensated liver cirrhosis: a case report.
BACKGROUND
Streptococcus pseudoporcinus (S. pseudoporcinus) was first identified in 2006. It cross-reacts with Lancefield group B antigen agglutination reagents and has been misidentified as S. agalactiae. Sites o... | ALBUMIN HUMAN, DAPTOMYCIN, FUROSEMIDE, HYDROCORTISONE, INSULIN GLARGINE, MEROPENEM, SPIRONOLACTONE, TERLIPRESSIN, VANCOMYCIN | DrugsGivenReaction | CC BY | 33992114 | 20,118,969 | 2021-05-16 |
What was the administration route of drug 'ALBUMIN HUMAN'? | Fatal Streptococcus pseudoporcinus disseminated infection in decompensated liver cirrhosis: a case report.
BACKGROUND
Streptococcus pseudoporcinus (S. pseudoporcinus) was first identified in 2006. It cross-reacts with Lancefield group B antigen agglutination reagents and has been misidentified as S. agalactiae. Sites o... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33992114 | 19,537,572 | 2021-05-16 |
What was the administration route of drug 'DAPTOMYCIN'? | Fatal Streptococcus pseudoporcinus disseminated infection in decompensated liver cirrhosis: a case report.
BACKGROUND
Streptococcus pseudoporcinus (S. pseudoporcinus) was first identified in 2006. It cross-reacts with Lancefield group B antigen agglutination reagents and has been misidentified as S. agalactiae. Sites o... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33992114 | 19,537,572 | 2021-05-16 |
What was the administration route of drug 'HYDROCORTISONE'? | Fatal Streptococcus pseudoporcinus disseminated infection in decompensated liver cirrhosis: a case report.
BACKGROUND
Streptococcus pseudoporcinus (S. pseudoporcinus) was first identified in 2006. It cross-reacts with Lancefield group B antigen agglutination reagents and has been misidentified as S. agalactiae. Sites o... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33992114 | 19,537,572 | 2021-05-16 |
What was the administration route of drug 'MEROPENEM'? | Fatal Streptococcus pseudoporcinus disseminated infection in decompensated liver cirrhosis: a case report.
BACKGROUND
Streptococcus pseudoporcinus (S. pseudoporcinus) was first identified in 2006. It cross-reacts with Lancefield group B antigen agglutination reagents and has been misidentified as S. agalactiae. Sites o... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33992114 | 20,118,969 | 2021-05-16 |
What was the outcome of reaction 'Drug ineffective'? | Fatal Streptococcus pseudoporcinus disseminated infection in decompensated liver cirrhosis: a case report.
BACKGROUND
Streptococcus pseudoporcinus (S. pseudoporcinus) was first identified in 2006. It cross-reacts with Lancefield group B antigen agglutination reagents and has been misidentified as S. agalactiae. Sites o... | Fatal | ReactionOutcome | CC BY | 33992114 | 19,537,572 | 2021-05-16 |
What was the outcome of reaction 'Drug resistance'? | Fatal Streptococcus pseudoporcinus disseminated infection in decompensated liver cirrhosis: a case report.
BACKGROUND
Streptococcus pseudoporcinus (S. pseudoporcinus) was first identified in 2006. It cross-reacts with Lancefield group B antigen agglutination reagents and has been misidentified as S. agalactiae. Sites o... | Fatal | ReactionOutcome | CC BY | 33992114 | 20,058,440 | 2021-05-16 |
What was the outcome of reaction 'Multiple organ dysfunction syndrome'? | Fatal Streptococcus pseudoporcinus disseminated infection in decompensated liver cirrhosis: a case report.
BACKGROUND
Streptococcus pseudoporcinus (S. pseudoporcinus) was first identified in 2006. It cross-reacts with Lancefield group B antigen agglutination reagents and has been misidentified as S. agalactiae. Sites o... | Fatal | ReactionOutcome | CC BY | 33992114 | 20,058,440 | 2021-05-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Autoimmune nephritis'. | Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
BACKGROUND Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However... | HYDRALAZINE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33993184 | 19,513,022 | 2021-05-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Glomerulonephritis rapidly progressive'. | Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
BACKGROUND Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However... | AMLODIPINE BESYLATE, ATORVASTATIN, HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, LABETALOL\LABETALOL HYDROCHLORIDE, LEVOTHYROXINE, LOSARTAN, METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33993184 | 19,455,808 | 2021-05-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hyperphosphataemia'. | Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
BACKGROUND Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However... | AMLODIPINE BESYLATE, ATORVASTATIN, HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, LABETALOL\LABETALOL HYDROCHLORIDE, LEVOTHYROXINE, LOSARTAN, METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33993184 | 19,430,379 | 2021-05-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Renal impairment'. | Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
BACKGROUND Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However... | AMLODIPINE BESYLATE, ATORVASTATIN, HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, LABETALOL\LABETALOL HYDROCHLORIDE, LEVOTHYROXINE, LOSARTAN, METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33993184 | 19,377,716 | 2021-05-16 |
What was the dosage of drug 'AMLODIPINE BESYLATE'? | Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
BACKGROUND Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However... | FOR 10 YEARS | DrugDosageText | CC BY-NC-ND | 33993184 | 19,356,323 | 2021-05-16 |
What was the dosage of drug 'HYDROCHLOROTHIAZIDE'? | Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
BACKGROUND Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However... | FOR 10 YEARS | DrugDosageText | CC BY-NC-ND | 33993184 | 19,356,323 | 2021-05-16 |
What was the dosage of drug 'LABETALOL\LABETALOL HYDROCHLORIDE'? | Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
BACKGROUND Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However... | FOR 10 YEARS | DrugDosageText | CC BY-NC-ND | 33993184 | 19,356,323 | 2021-05-16 |
What was the dosage of drug 'LEVOTHYROXINE'? | Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
BACKGROUND Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However... | FOR 2 YEARS | DrugDosageText | CC BY-NC-ND | 33993184 | 19,356,323 | 2021-05-16 |
What was the dosage of drug 'LOSARTAN'? | Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
BACKGROUND Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However... | FOR 5 YEARS | DrugDosageText | CC BY-NC-ND | 33993184 | 19,356,323 | 2021-05-16 |
What was the dosage of drug 'METFORMIN HYDROCHLORIDE'? | Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
BACKGROUND Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However... | FOR 7 YEAR | DrugDosageText | CC BY-NC-ND | 33993184 | 19,356,323 | 2021-05-16 |
What was the outcome of reaction 'Autoimmune nephritis'? | Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
BACKGROUND Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However... | Not recovered | ReactionOutcome | CC BY-NC-ND | 33993184 | 19,513,022 | 2021-05-16 |
What was the outcome of reaction 'Hyperphosphataemia'? | Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
BACKGROUND Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However... | Recovering | ReactionOutcome | CC BY-NC-ND | 33993184 | 19,430,379 | 2021-05-16 |
What was the outcome of reaction 'Renal impairment'? | Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
BACKGROUND Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However... | Recovering | ReactionOutcome | CC BY-NC-ND | 33993184 | 19,377,716 | 2021-05-16 |
What was the administration route of drug 'AMIODARONE'? | Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
BACKGROUND
The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33993888 | 19,509,858 | 2021-05-17 |
What was the administration route of drug 'ASPIRIN'? | Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
BACKGROUND
The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death... | Oral | DrugAdministrationRoute | CC BY | 33993888 | 19,423,889 | 2021-05-17 |
What was the administration route of drug 'BISOPROLOL'? | Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
BACKGROUND
The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death... | Oral | DrugAdministrationRoute | CC BY | 33993888 | 19,423,889 | 2021-05-17 |
What was the administration route of drug 'FENTANYL'? | Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
BACKGROUND
The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33993888 | 19,509,858 | 2021-05-17 |
What was the administration route of drug 'MAGNESIUM'? | Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
BACKGROUND
The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33993888 | 19,509,858 | 2021-05-17 |
What was the administration route of drug 'METOPROLOL'? | Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
BACKGROUND
The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33993888 | 19,509,858 | 2021-05-17 |
What was the administration route of drug 'MORPHINE'? | Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
BACKGROUND
The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33993888 | 19,509,858 | 2021-05-17 |
What was the administration route of drug 'PIPERACILLIN SODIUM\TAZOBACTAM SODIUM'? | Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
BACKGROUND
The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33993888 | 19,423,889 | 2021-05-17 |
What was the administration route of drug 'PROPOFOL'? | Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
BACKGROUND
The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33993888 | 19,509,858 | 2021-05-17 |
What was the administration route of drug 'RAMIPRIL'? | Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
BACKGROUND
The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death... | Oral | DrugAdministrationRoute | CC BY | 33993888 | 19,423,889 | 2021-05-17 |
What was the administration route of drug 'ROCURONIUM BROMIDE'? | Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
BACKGROUND
The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33993888 | 19,423,889 | 2021-05-17 |
What was the administration route of drug 'SPIRONOLACTONE'? | Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
BACKGROUND
The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death... | Oral | DrugAdministrationRoute | CC BY | 33993888 | 19,423,889 | 2021-05-17 |
What was the administration route of drug 'TICAGRELOR'? | Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
BACKGROUND
The implantation of cardioverter defibrillators (ICDs) is an established therapy in the prevention of sudden cardiac death... | Oral | DrugAdministrationRoute | CC BY | 33993888 | 19,423,889 | 2021-05-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Atypical mycobacterial infection'. | Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer.
Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result... | BEVACIZUMAB, DEXAMETHASONE, NIVOLUMAB, PACLITAXEL | DrugsGivenReaction | CC BY-NC-ND | 33994435 | 20,155,240 | 2021-11-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Device related infection'. | Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer.
Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result... | BEVACIZUMAB, DEXAMETHASONE, NIVOLUMAB, PACLITAXEL | DrugsGivenReaction | CC BY-NC-ND | 33994435 | 20,155,240 | 2021-11-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Device related thrombosis'. | Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer.
Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result... | BEVACIZUMAB, DEXAMETHASONE, NIVOLUMAB, PACLITAXEL | DrugsGivenReaction | CC BY-NC-ND | 33994435 | 20,155,240 | 2021-11-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer.
Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result... | AMIKACIN, BEVACIZUMAB, CIPROFLOXACIN, DOXORUBICIN, LEUPROLIDE ACETATE, NIVOLUMAB, PACLITAXEL, RIVAROXABAN, TAMOXIFEN | DrugsGivenReaction | CC BY-NC-ND | 33994435 | 20,683,554 | 2021-11-01 |
What was the administration route of drug 'BEVACIZUMAB'? | Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer.
Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result... | Intravenous drip | DrugAdministrationRoute | CC BY-NC-ND | 33994435 | 20,155,240 | 2021-11-01 |
What was the administration route of drug 'NIVOLUMAB'? | Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer.
Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result... | Intravenous drip | DrugAdministrationRoute | CC BY-NC-ND | 33994435 | 20,155,240 | 2021-11-01 |
What was the administration route of drug 'PACLITAXEL'? | Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer.
Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result... | Intravenous drip | DrugAdministrationRoute | CC BY-NC-ND | 33994435 | 20,155,240 | 2021-11-01 |
What was the dosage of drug 'DOXORUBICIN'? | Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer.
Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result... | ADJUVANT CHEMOTHERAPY | DrugDosageText | CC BY-NC-ND | 33994435 | 20,683,554 | 2021-11-01 |
What was the dosage of drug 'LEUPROLIDE ACETATE'? | Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer.
Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result... | HORMONE THERAPY | DrugDosageText | CC BY-NC-ND | 33994435 | 20,683,554 | 2021-11-01 |
What was the dosage of drug 'TAMOXIFEN'? | Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer.
Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result... | HORMONE THERAPY | DrugDosageText | CC BY-NC-ND | 33994435 | 20,683,554 | 2021-11-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Liver Cirrhosis Complicated by Spontaneous Bacterial Peritonitis Caused by the Burkholderia cepacia Complex.
A 79-year-old man with underlying alcoholic liver cirrhosis presented with complaints of a fever, abdominal pain, and difficulty walking. A diagnostic work-up revealed liver atrophy and chylous ascites, and spon... | ALBUMIN HUMAN, CEFTRIAXONE SODIUM, LEVOFLOXACIN, MEROPENEM, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY-NC-ND | 33994438 | 21,004,509 | 2021-11-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Multiple organ dysfunction syndrome'. | Liver Cirrhosis Complicated by Spontaneous Bacterial Peritonitis Caused by the Burkholderia cepacia Complex.
A 79-year-old man with underlying alcoholic liver cirrhosis presented with complaints of a fever, abdominal pain, and difficulty walking. A diagnostic work-up revealed liver atrophy and chylous ascites, and spon... | ALBUMIN HUMAN, CEFTRIAXONE SODIUM, LEVOFLOXACIN, MEROPENEM, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY-NC-ND | 33994438 | 21,004,509 | 2021-11-01 |
What is the weight of the patient? | Liver Cirrhosis Complicated by Spontaneous Bacterial Peritonitis Caused by the Burkholderia cepacia Complex.
A 79-year-old man with underlying alcoholic liver cirrhosis presented with complaints of a fever, abdominal pain, and difficulty walking. A diagnostic work-up revealed liver atrophy and chylous ascites, and spon... | 51.7 kg. | Weight | CC BY-NC-ND | 33994438 | 21,004,509 | 2021-11-01 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.